ClinicalTrials.gg
CompletedNCT01712789STRATUSUpdated Jan 10, 2022Results posted

Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

A Phase 3 interventional study of Pomalidomide and Dexamethasone in Multiple Myeloma, sponsored by Celgene. Completed at 112 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-10.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
682
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.

Enrollment
4th of 102
682 · median 50
Started
2012
with 6 others
Phase 3
17 of 102
3 open now
Registered
17th of 102
by date
Lead sponsor
10 of 102
Celgene

Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 4th largest by enrollment, is one of 7 that started in 2012, is one of 17 in phase 3, and was the 17th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About pomalidomide

pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies testing pomalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the safety and efficacy and to generate PK and biomarker data for the combination of pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma.

The study consists of a Screening phase within 28 days prior to cycle 1 day 1, a Treatment phase and a Follow-up phase which starts within 28 days of discontinuation from study treatment, every 3 months for up to 5 years.

In addition, the collection of steady-state PK data from a large population will enable robust population PK and assess Pomalidomide exposure response analyses.

The exploratory objectives of the study are to investigate potential markers predictive of POM response or resistance and pharmacodynamic markers.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Relapsed and refractory Multiple Myeloma
  • Pomalidomide
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥18 years old, who must understand and voluntarily sign an .
  • Patients must have documented diagnosis of Multiple Myeloma and have .
  • Patients must have undergone prior treatment with ≥ 2 treatments lines, of anti-myeloma therapy.
  • Patients must have either or relapsed and refractory disease.
  • Patients must have received at least 2 consecutive cycles of prior treatment that include lenalidomide and bortezomib, either alone or in combination regimens.
  • Patients must have received adequate alkylator therapy

Exclusion criteria

Exclusion Criteria:

  • Prior history of , other than Multiple Myeloma.
  • Previous therapy with Pomalidomide, to thalidomide and lenalidomide or dexamethasone.
  • Patients who received an allogeneic bone marrow or peripheral blood stem cell transplant.
  • Patients who are planning for or who are eligible for stem cell transplant.
  • Patients who received major surgery and any anti-myeloma drug therapy within the last 14 days of starting study treatment.
  • Patients with a current disease that can interfere with protocol procedures or study treatment.
  • Patients unable or unwilling to undergo antithrombotic prophylactic treatment.
  • Pregnant or breastfeeding females.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
682 participants (actual)

Study arms

  • Experimental
    Pomalidomide plus Dexamethasone

    Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.

    Drug: Pomalidomide · Drug: Dexamethasone

Interventions

  • Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle

  • Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE)

    An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, regardless of etiology. Any worsening (i.e., any significant adverse change in the frequency or intensity of a pre- existing condition) was considered an AE. The severity of AEs were graded based on the symptoms according to version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events. Second primary malignancies were monitored as events of interest and considered as part of the assessment of AEs. A SAE = AE occurring at any dose that: * Results in death; * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect

    Time frame: From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.

Secondary outcomes

  1. Overall Response

    Overall response rate (ORR) was defined as the percentage of participants with a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) according to the International Myeloma Working Group uniform response criteria (IMWG URC) assessed by the Investigator. Responses must have been confirmed at at least 2 consecutive assessments before the institution of any new therapy with no known evidence of progressive or new bone lesions

    Time frame: Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks

  2. Time to Response

    Time to response was defined as the time from treatment enrollment to the first documentation of response (sCR, CR, VGPR or PR) based on IMWG criteria.

    Time frame: Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks

  3. Kaplan Meier Estimate of Duration of Response

    Duration of response, calculated for responders only, was defined as time from the initial documented response (SCR, CR, VGPR or PR) to the first confirmed disease progression, or death if no disease progression was recorded. Participants without a documented progression were censored at the time of their last tumor assessment.

    Time frame: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months

  4. Kaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines

    Progression free survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until either PD or death (any cause). Participants without an event (either a documented PD or death) at the time of study end were censored at the time of their last documented disease assessment or at the IVRS enrollment date if no disease assessment was conducted.

    Time frame: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months

  5. Kaplan Meier Estimate of Time to Progression

    Time to progression was calculated as the time from study enrollment until first recorded disease progression as determined by the site investigator based on the IMWG criteria, or until death due to progression. Participants not experiencing a documented progression were censored at the time of their last tumor assessment (or at the time of trial enrollment if no assessment was conducted).

    Time frame: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months

  6. Kaplan Meier Estimate of Overall Survival (OS)

    Overall survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until death due to any cause. Participants who did not have death data at the time of study end/analysis were censored at the time they were last known to be alive.

    Time frame: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months

  7. Pomalidomide Exposure - Apparent (Oral) Clearance (CL/F)

    Pharmacokinetic (PK) parameters are derived from pomalidomide concentration versus time data.

    Time frame: Cycles 1, 2, 3, 4, 5, 6

  8. Pomalidomide Exposure - Apparent Volume of Distribution (V/F)

    Pharmacokinetic (PK) parameters are derived from Pomalidomide concentration versus time data.

    Time frame: Cycles 1, 2, 3, 4, 5, 6

  9. Cytogenetic Analysis

    Cytogenetic analysis was to be performed using fluorescence in situ hybridization (FISH) methodology at a local laboratory, to evaluate the relationship between cytogenetic profiles and the combination of POM and LD-DEX in terms of response and outcome.

    Time frame: Study entry

07

Results

Posted Jan 10, 2022

Participant flow

The study was conducted at 112 sites: 4 in Austria, 7 in Belgium, 3 in Denmark, 1 in Estonia, 2 in Finland, 13 in France, 17 in Germany, 1 in Greece, 3 in Ireland, 15 in Italy, 5 in the Netherlands, 2 in Norway, 3 in Poland, 4 in Portugal, 1 in Slovakia, 15 in Spain, 2 in Sweden, 3 in Switzerland, 2 in Turkey, and 9 in the United Kingdom.

Participant flow — Overall Study
MilestonePomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Started682
Received study treatment676
Completed0
Not completed682
Withdrew: Lack of efficacy2
Withdrew: Lost to follow-up1
Withdrew: Progressive disease504
Withdrew: Death57
Withdrew: Adverse event52
Withdrew: Miscellaneous31
Withdrew: Withdrawal by subject21
Withdrew: Transition to commercial treatment8
Withdrew: Participants did not receive study drug6

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAE)

An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, regardless of etiology. Any worsening (i.e., any significant adverse change in the frequency or intensity of a pre- existing condition) was considered an AE. The severity of AEs were graded based on the symptoms according to version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events. Second primary malignancies were monitored as events of interest and considered as part of the assessment of AEs. A SAE = AE occurring at any dose that: * Results in death; * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect

Time frame:
From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE)
ParticipantsPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
≥ TEAE673
≥ 1 TEAE Related to Pomalidomide (POM)527
≥ 1 TEAE Related to LD-Dex448
≥ 1 TEAE Related to Either POM or LD-Dex575
≥ 1 Grade (Gr) 3 or 4 TEAE606
≥ 1 Gr 3 or 4 TEAE Related to (R/T) POM417
≥ 1 Gr 3 or 4 TEAE R/T LD-Dex226
≥ 1 Gr 3 or 4 TEAE R/T Either POM or LD-Dex448
≥ 1 Grade 5 TEAE127
≥ 1 Grade 5 TEAE R/T POM14
≥ 1 Grade 5 TEAE R/T LD-Dex16
≥ 1 Grade 5 TEAE R/T either POM or LD-Dex18
≥ 1 Serious TEAE448
≥ 1 Serious TEAE R/T POM187
≥ 1 Serious TEAE R/T LD-Dex146
≥ 1 Serious TEAE R/T Either POM or LD-Dex215
≥ 1 Serious TEAE Leading to (L/T)Stopping of POM36
≥ 1 Serious TEAE L/T Stopping of LD-Dex34
≥1 Serious TEAE L/T Stopping either POM or LD-Dex37
≥ 1 TEAE L/T to Stopping of POM54
≥ 1 TEAE L/T to Stopping of LD-DEX61
≥ 1 TEAE L/T to Stopping of Either POM or LD-DEX63
≥1 Study Drug Related TEAE (L/T) Stopping POM30
≥1 Study Drug Related TEAE L/T Stopping LD-Dex19
≥1 Drug Related TEAE L/T Stopping LD-Dex or POM38
≥ 1 TEAE L/T to Reduction (R/D) of POM164
≥ 1 TEAE L/T to R/D of LD-DEX150
≥ 1 TEAE L/T to R/D of Either POM or LD-DEX244
≥ 1 Study Drug Related TEAE L/T to R/D of POM142
≥ 1 Study Drug Related TEAE L/T to R/D of LD-DEX135
≥1 StudyDrug Related TEAE L/T to R/D POM or LD-DEX224
≥ 1 TEAE L/T to Interruption (I/R) of POM455
≥ 1 TEAE L/T to I/R of LD-DEX434
≥ 1 TEAE L/T to I/R of either POM or LD-DEX470
≥ 1 Study Drug Related TEAE L/T to I/R of POM294
≥ 1 Study Drug Related TEAE L/T to I/R of LD-DEX185
≥1 StudyDrug Related TEAE L/T to I/R POM or LD-DEX333
SecondaryOverall Response

Overall response rate (ORR) was defined as the percentage of participants with a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) according to the International Myeloma Working Group uniform response criteria (IMWG URC) assessed by the Investigator. Responses must have been confirmed at at least 2 consecutive assessments before the institution of any new therapy with no known evidence of progressive or new bone lesions

Time frame:
Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks
Reported as:
Number · Percentage of Participants
Overall Response
Percentage of ParticipantsPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Overall Response33.4 (29.9 to 37.1)
SecondaryTime to Response

Time to response was defined as the time from treatment enrollment to the first documentation of response (sCR, CR, VGPR or PR) based on IMWG criteria.

Time frame:
Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks
Reported as:
Median · Weeks
Time to Response
WeeksPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Time to Response8.1 (2 to 112)
SecondaryKaplan Meier Estimate of Duration of Response

Duration of response, calculated for responders only, was defined as time from the initial documented response (SCR, CR, VGPR or PR) to the first confirmed disease progression, or death if no disease progression was recorded. Participants without a documented progression were censored at the time of their last tumor assessment.

Time frame:
From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
Reported as:
Median · Months
Kaplan Meier Estimate of Duration of Response
MonthsPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Kaplan Meier Estimate of Duration of Response7.9 (6.48 to 8.78)
SecondaryKaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines

Progression free survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until either PD or death (any cause). Participants without an event (either a documented PD or death) at the time of study end were censored at the time of their last documented disease assessment or at the IVRS enrollment date if no disease assessment was conducted.

Time frame:
From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
Reported as:
Median · Months
Kaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines
MonthsPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Kaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines4.6 (3.91 to 4.90)
SecondaryKaplan Meier Estimate of Time to Progression

Time to progression was calculated as the time from study enrollment until first recorded disease progression as determined by the site investigator based on the IMWG criteria, or until death due to progression. Participants not experiencing a documented progression were censored at the time of their last tumor assessment (or at the time of trial enrollment if no assessment was conducted).

Time frame:
From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
Reported as:
Median · Months
Kaplan Meier Estimate of Time to Progression
MonthsPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Kaplan Meier Estimate of Time to Progression4.8 (4.27 to 5.56)
SecondaryKaplan Meier Estimate of Overall Survival (OS)

Overall survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until death due to any cause. Participants who did not have death data at the time of study end/analysis were censored at the time they were last known to be alive.

Time frame:
From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
Reported as:
Median · Months
Kaplan Meier Estimate of Overall Survival (OS)
MonthsPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Kaplan Meier Estimate of Overall Survival (OS)11.9 (10.65 to 13.41)
SecondaryPomalidomide Exposure - Apparent (Oral) Clearance (CL/F)

Pharmacokinetic (PK) parameters are derived from pomalidomide concentration versus time data.

Time frame:
Cycles 1, 2, 3, 4, 5, 6
Reported as:
Median · Liters/hour
Pomalidomide Exposure - Apparent (Oral) Clearance (CL/F)
Liters/hourPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Pomalidomide Exposure - Apparent (Oral) Clearance (CL/F)6.02 (5.67 to 6.48)
SecondaryPomalidomide Exposure - Apparent Volume of Distribution (V/F)

Pharmacokinetic (PK) parameters are derived from Pomalidomide concentration versus time data.

Time frame:
Cycles 1, 2, 3, 4, 5, 6
Reported as:
Median · Liters
Pomalidomide Exposure - Apparent Volume of Distribution (V/F)
LitersPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Pomalidomide Exposure - Apparent Volume of Distribution (V/F)75.10 (63.57 to 89.17)
SecondaryCytogenetic Analysis

Cytogenetic analysis was to be performed using fluorescence in situ hybridization (FISH) methodology at a local laboratory, to evaluate the relationship between cytogenetic profiles and the combination of POM and LD-DEX in terms of response and outcome.

Time frame:
Study entry

No measurements were reported for this outcome.

Adverse events

Collected over All-cause mortality is reported from enrollment until the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months. Adverse events are reported from first dose of study drug up to 28 days after last dose; median duration of treatment was 21.4 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)598/682 (87.7%)448/676 (66.3%)646/676 (95.6%)
Most frequent serious events
Showing 10 of 298
Most frequent serious events
EventPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
PneumoniaInfections and infestations117/676
General physical health deteriorationGeneral disorders45/676
PyrexiaGeneral disorders41/676
Febrile neutropeniaBlood and lymphatic system disorders34/676
HypercalcaemiaMetabolism and nutrition disorders30/676
Acute kidney injuryRenal and urinary disorders26/676
Renal failureRenal and urinary disorders23/676
Lower respiratory tract infectionInfections and infestations22/676
NeutropeniaBlood and lymphatic system disorders20/676
Atrial fibrillationCardiac disorders17/676
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPomalidomide Plus Low Dose Dexamethasone (LD-Dex)
NeutropeniaBlood and lymphatic system disorders382/676
AnaemiaBlood and lymphatic system disorders327/676
ThrombocytopeniaBlood and lymphatic system disorders236/676
FatigueGeneral disorders197/676
PyrexiaGeneral disorders178/676
ConstipationGastrointestinal disorders163/676
AstheniaGeneral disorders155/676
CoughRespiratory, thoracic and mediastinal disorders141/676
DiarrhoeaGastrointestinal disorders118/676
DyspnoeaRespiratory, thoracic and mediastinal disorders117/676

Baseline characteristics

The intent to treat (ITT) population was defined as all enrolled participants (participants who received an interactive voice response system (IVRS) enrollment date) regardless of whether they received any investigational product (IP) or not.

Age, Continuous
Age, Continuous(Years)Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Mean65.4 ± 9.10
Sex: Female, Male
Sex: Female, Male(Participants)Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Female301
Male381
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Hispanic or Latino52
Not Hispanic or Latino626
Unknown or Not Reported4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Asian3
Black or African American4
White669
Other2
Missing4
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)
0 = Fully active, no restrictions295
1 = Restricted activity but ambulatory319
2 = Ambulatory and capable of all self-care67
3 = Limited self-care1
4 = Completely disabled0
Time since diagnosis
Time since diagnosis(Years)Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Mean6.15 ± 3.649
Beta 2 Microglobulin
Beta 2 Microglobulin(mg/L)Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Mean5.48 ± 4.713
Serum Light Chain Type
Serum Light Chain Type(Participants)Pomalidomide Plus Low Dose Dexamethasone (LD-Dex)
Kappa364
Lambda230
No Serum Light chain Type Detected16
Test Not Performed72

3 further baseline measures are reported on the registry.

08

Study locations

112 sites
  • Medical University of Graz
    Graz, A-8036, Austria
  • Medizinische Universitat Innsbruck
    Innsbruck, 6020, Austria
  • Wilhelminenspital Vienna
    Vienna, 1160, Austria
  • Medical University of Vienna
    Vienna, A-1090, Austria
  • AZ St-Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • VUB Vrije Universiteit Brussel
    Brussel, 1090, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege
    Liege, 4000, Belgium
  • CHU Mont -Godinne
    Yvoir, 5530, Belgium
  • Aarhus University Hospital
    Aarhus, 8000, Denmark
  • Odense University Hospital
    Odense, DK-5000, Denmark
  • Vejle Hospital
    Vejle, 7100, Denmark
  • Tartu University Hospital Clinic
    Tartu, 51014, Estonia
  • Helsingin yliopistollinen keskussairaala
    Helsinki, FI-00290, Finland
  • Turku University Hospital
    Turku, 20521, Finland
  • Centre Hospitalier de la cote basque
    Bayonne, 64109, France
  • Hopital Henri Mondor
    Créteil, 94010, France
  • Hopital A. Michallon
    La Tronche, 38700, France
  • CHRU Claude Huriez
    Lille, 59037, France
  • Institut Paoli Calmette Hematologie
    Marseille cedex, 13273, France
  • CHU Hotel Dieu
    Nantes, 44093, France
  • Hopital Saint Antoine
    Paris, 75012, France
  • Service Hemato-Immunologie Hopital St Louis
    Paris, 75475, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite, 69495, France
  • CHU de Reims
    Reims cedex, 51092, France
  • Hematologie - CHU Purpan
    Toulouse, 31059, France
  • CHRU Hopital Bretonneau
    Tours cedex, 37044, France
  • CHU Nancy Hematology
    Vandoeuvre les Nancy, 54511, France
  • Charite, Campus Benjamin Franklin Universitatsmedizin Berlin
    Berlin, 12200, Germany
  • Klinikum Chemnitz
    Chemnitz, D-09113, Germany
  • Universitatsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Universitatsklinkikum DusseldorfKlinik fur Hamatologie, Onkologie und klin. Immunoligie
    Dusseldorf, D-40225, Germany
  • Universitatsklinikum Essen-
    Essen, 45122, Germany
  • Universitatsklinikum Freiburg Medizinische Klinik und Poliklinik
    Freiburg, D-79106, Germany
  • Abt Haematologie - Onkologie / Allg. Krankenhaus Altona
    Hamburg, D-22763, Germany
  • Universitatsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitatsklinikum Jena
    Jena, O7740, Germany
  • University of Schleswig Holstein
    Kiel, 24105, Germany
  • Klinikum der Universitat zu Koln
    Köln, 50937, Germany
  • Universitatsklinikum Leipzig
    Leipzig, 04103, Germany
  • Universitatsklinik MuensterMedizinische Klinik A
    Muenster, 48129, Germany
  • TU München - Klinikum rechts der Isar
    München, 81675, Germany
  • UKT Universitaetsklinikum Tuebingen
    Tuebingen, 72076, Germany
  • University Hospital of Ulm
    Ulm, 89081, Germany
  • Universitatsklinikum Wurzburg
    Würzburg, 97080, Germany
  • University of Athens
    Athens, 11528, Greece
  • Cork University HospitalHaematology Consultant
    Wilton, Cork, Ireland
  • Mater Misericordiae University Hospital
    Dublin, Dublin 7, Ireland
  • University Hospital Galway
    Galway, ST46QG, Ireland
  • Ospedali Riuniti di Ancona
    Ancona, 60126, Italy
  • A.O. Policlinico - Università di Bari
    Bari, 70124, Italy
  • University of Bologna
    Bologna, 40138, Italy
  • Ospedale Ferrarotto
    Catania, 95124, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milano, 20133, Italy
  • ASST Grande Ospedale Metropolitano Niguarda, Milano
    Milano, 20162, Italy
  • Universita degli Studi di Padova
    Padova, 35128, Italy
  • Casa di Cura La Maddalena
    Palermo, 90146, Italy
  • Ospedale Civile di Piacenza
    Piacenza, 29100, Italy
  • Azienda Ospedaliero-Universitaria Pisana
    Pisa, 56126, Italy
  • Universita degli Studi di Roma La Sapienza - Azienda Policlinico Umberto I
    Roma, 00168, Italy
  • Ospedale Sant'Eugenio
    Rome, 00144, Italy
  • Azienda Ospedaliera San Giovanni Battista - Ospedale Molinette
    Torino, 10126, Italy
  • Azienda Ospedaliero-Universitaria Santa Maria della Misericordia die Udine
    Udine, 33100, Italy
  • Ospedale San Bortolo
    Vicenza, 36100, Italy
  • VU University Medical Center VU Medisch Centrum
    Amsterdam, 1081 HV, Netherlands
  • Haga Hospital
    Den Haag, 2545 CH, Netherlands
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 GZ, Netherlands
  • Erasmus Medical Center
    Rotterdam, 3015 CE, Netherlands
  • University Medical Center Utrecht
    Utrecht, 3584 CX, Netherlands
  • Oslo University Hospital, Rikshospitalet HF
    Oslo, 0424, Norway
  • St. Olavs Hospital Trondheim
    Trondheim, N-7006, Norway
  • Akademia Medyczna w Gdansku Katedra i Klinika Hematologii i Transplantologii
    Gdansk, 80-211, Poland
  • Szpitala Uniwersyteckiego w. Krakowie
    Kraków, 31 501, Poland
  • Instytut Hematologii i Transfuzjologii w Warszawie
    Warszawa, 02-776, Poland
  • Hospital Universitario de Coimbra- Hospitais de Universidade de Coimbra
    Coimbra, 3000-075, Portugal
  • Instituto Portugues de Oncologia de Lisboa
    Lisboa, 1099-023, Portugal
  • Hospital de Santa Maria
    Lisboa, 1649-035, Portugal
  • Hospital Geral de Santo António - Serviço de Hematologia Clínica
    Porto, 4099-001, Portugal
  • University Hospital Bratislava - Hospital Ss Cyril and Methodius
    Bratislava, 85107, Slovakia
  • Hospital Universitari Germans Trias i Pujol
    Badalona (Barcelona), 8916, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitario de Canarias
    La Laguna (Tenerife), 38320, Spain
  • Hospital de La Princesa
    Madrid, 28006, Spain
  • Hospital Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen De La Victoria
    Malaga, 29010, Spain
  • Hospital Morales Meseguer
    Murcia, 30008, Spain
  • Clinica Universidad de Navarra
    Pamplona, 31008, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital de Donosti
    San Sebastián (Guipuzcoa), 20014, Spain
  • Hospital Clinico Universitario De Santiago De Compostela
    Santiago De Compostela, 15706, Spain
  • Hospital Virgen de la Salud
    Toledo, 45004, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Universitetssjukhuset i Lund
    Lund, SE-22185, Sweden
  • Karolinska University HospitalSolna
    Stockholm, SE 17176, Sweden
  • Universitatsspital Bern
    Bern, 3010, Switzerland
  • Hopitaux Universitaires de Geneve-HUG
    Genèva, 1211, Switzerland

Showing the first 100 of 112 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Rollig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 Jul 28;128(4):497-503. doi: 10.1182/blood-2016-02-700872. Epub 2016 May 25. PubMed 27226434 ↗
  • Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. Eur J Haematol. 2017 Sep;99(3):199-206. doi: 10.1111/ejh.12903. Epub 2017 Jun 14. PubMed 28504846 ↗
  • Qian X, Dimopoulos MA, Amatangelo M, Bjorklund C, Towfic F, Flynt E, Weisel KC, Ocio EM, Yu X, Peluso T, Sternas L, Zaki M, Moreau P, Thakurta A. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. Leuk Lymphoma. 2019 Feb;60(2):462-470. doi: 10.1080/10428194.2018.1485915. Epub 2018 Aug 2. PubMed 30068263 ↗
  • Siegel DS, Weisel KC, Dimopoulos MA, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leuk Lymphoma. 2016 Dec;57(12):2833-2838. doi: 10.1080/10428194.2016.1177181. Epub 2016 Jun 7. PubMed 27267105 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Dec 2019, 85 months.

Results were first posted in Jan 2022, 2 years after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 85 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2012
First posted
Oct 24, 2012
StartActual
Nov 6, 2012
Primary completionActual
Dec 11, 2019
CompletionActual
Dec 11, 2019
Results first posted
Jan 10, 2022
Last update
Jan 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01712789
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 24, 2012
Start date
Nov 6, 2012
Primary completion
Dec 11, 2019
Completion
Dec 11, 2019
Results posted
Jan 10, 2022
Last update
Jan 10, 2022

Study contacts

Teresa Peluso, MBBS, DCPSA
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion